(original) (raw)

TY - JOUR AU - Cang, Shundong AU - Mukhi, Nikhil AU - Wang, Kemeng AU - Liu, Delong PY - 2012 DA - 2012/10/11 TI - Novel CD20 monoclonal antibodies for lymphoma therapy JO - Journal of Hematology & Oncology SP - 64 VL - 5 IS - 1 AB - Rituximab (RTX), a monoclonal antibody (mAb) against CD20, has been widely used for lymphoma therapy. RTX in combination with cyclophosphamide /doxorubicin /vincristine /prednisone (R-CHOP) remains the standard frontline regimen for diffuse large B-cell lymphoma. However, suboptimal response and /or resistance to rituximab have remained a challenge in the therapy of B-cell non-Hodgkin’s lymphoma (NHL). Novel agents are under active clinical trials. This review will summarize the latest development in new mAbs against CD20, which include second-generation mAbs, ofatumumab, veltuzumab (IMMU-106), ocrelizumab (PRO70769), and third-generation mAbs, AME-133v (ocaratuzumab), PRO131921 and GA101 (obinutumumab). SN - 1756-8722 UR - https://doi.org/10.1186/1756-8722-5-64 DO - 10.1186/1756-8722-5-64 ID - Cang2012 ER -